Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug 14;16(8):1294.
doi: 10.3390/v16081294.

EBV Reactivation and Disease in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients and Its Impact on HSCT Outcomes

Nancy Law  1 , Cathy Logan  1 , Randy Taplitz  2
Affiliations
Review

EBV Reactivation and Disease in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients and Its Impact on HSCT Outcomes

Nancy Law et al. Viruses. .

Abstract

The acquisition or reactivation of Epstein-Barr virus (EBV) after allogeneic Hematopoietic Stem Cell Transplant (HSCT) can be associated with complications including the development of post-transplant lymphoproliferative disorder (PTLD), which is associated with significant morbidity and mortality. A number of risk factors for PTLD have been defined, including T-cell depletion, and approaches to monitoring EBV, especially in high-risk patients, with the use of preemptive therapy upon viral activation have been described. Newer therapies for the preemption or treatment of PTLD, such as EBV-specific cytotoxic T-cells, hold promise. Further studies to help define risks, diagnosis, and treatment of EBV-related complications are needed in this at-risk population.

Keywords: EBV-specific cytotoxic T-cells; Epstein–Barr virus; allogeneic transplant; post-transplant lymphoproliferative disorder.

PubMed Disclaimer

Conflict of interest statement

Randy Taplitz: Karius Advisory Board; Cathy Logan: none to declare; Nancy Law: none to declare.

References

    1. Nowalk A., Green M. Epstein-Barr Virus. Microbiol. Spectr. 2016;4:10–1128. doi: 10.1128/microbiolspec.DMIH2-0011-2015. - DOI - PubMed
    1. El-Mallawany N.K., Curry C.V., Allen C.E. Haemophagocytic lymphohistiocytosis and Epstein-Barr virus: A complex relationship with diverse origins, expression and outcomes. Br. J. Haematol. 2022;196:31–44. doi: 10.1111/bjh.17638. - DOI - PubMed
    1. Marjanska A., Styczynski J. Who is the patient at risk for EBV reactivation and disease: Expert opinion focused on post-transplant lymphoproliferative disorders following hematopoietic stem cell transplantation. Expert. Opin. Biol. Ther. 2023;23:539–552. doi: 10.1080/14712598.2023.2196366. - DOI - PubMed
    1. Styczynski J., Gil L., Tridello G., Ljungman P., Donnelly J.P., van der Velden W., Omar H., Martino R., Halkes C., Faraci M., et al. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: A study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Clin. Infect. Dis. 2013;57:794–802. doi: 10.1093/cid/cit391. - DOI - PubMed
    1. Tsushima T., Masuda S.I., Yoda N., Kainuma S., Kimeda C., Konno S., Tanaka K., Matsuo K., Shimoji S., Kimura K., et al. Clinical characteristics and outcomes of Epstein-Barr virus viral load after allogeneic hematopoietic stem cell transplantation. Ann. Hematol. 2024;103:935–946. doi: 10.1007/s00277-023-05596-6. - DOI - PMC - PubMed

MeSH terms